Knight Therapeutics Inc. GUD.TO
TSX
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 98.42M | 104.19M | 108.21M | 95.48M | 88.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.42M | 104.19M | 108.21M | 95.48M | 88.25M |
| Cost of Revenue | 49.51M | 53.89M | 57.83M | 49.05M | 47.73M |
| Gross Profit | 48.91M | 50.30M | 50.38M | 46.43M | 40.52M |
| SG&A Expenses | 27.37M | 26.47M | 25.11M | 25.43M | 22.52M |
| Depreciation & Amortization | 10.59M | 9.72M | 10.70M | 9.92M | 11.21M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.46M | 97.72M | 100.50M | 91.02M | 87.78M |
| Operating Income | 3.96M | 6.47M | 7.71M | 4.45M | 469.00K |
| Income Before Tax | -3.48M | -1.52M | 10.34M | 8.05M | -1.39M |
| Income Tax Expenses | -1.56M | 908.90K | 738.50K | 1.70M | 1.36M |
| Earnings from Continuing Operations | -1.92M | -2.43M | 9.60M | 6.35M | -2.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.92M | -2.43M | 9.60M | 6.35M | -2.75M |
| EBIT | 3.96M | 6.47M | 7.71M | 4.45M | 469.00K |
| EBITDA | 15.52M | 17.32M | 19.51M | 11.81M | 13.37M |
| EPS Basic | -0.02 | -0.02 | 0.10 | 0.06 | -0.03 |
| Normalized Basic EPS | 0.02 | 0.03 | 0.07 | 0.01 | 0.01 |
| EPS Diluted | -0.02 | -0.02 | 0.09 | 0.06 | -0.03 |
| Normalized Diluted EPS | 0.02 | 0.03 | 0.07 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 98.23M | 98.20M | 98.46M | 99.34M | 99.66M |
| Average Diluted Shares Outstanding | 98.23M | 98.20M | 98.93M | 99.86M | 99.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |